The Züri Can – "Cannabis with Responsibility" project in Zurich has set out to study the impact of legalization on society, exploring aspects such as public health, crime, and the economy. Preliminary findings indicate high participant engagement and positive reception, with diverse product offerings and regulated access points, contributing valuable data for future cannabis policy decisions.
The project Züri Can – “Cannabis with Responsibility” inaugurated in Zurich, where participants can legally purchase cannabis, aims to explore the impact of legalization on society. Conducted by the Addiction Disorder Research Group at the Psychiatric University Clinic Zurich, the experiment began in March 2023. Its goal is to provide scientific evidence on the consequences of legal cannabis distribution.
Züri Can responds to the growing global interest in regulating cannabis access and the potential benefits such an approach might have for public health, crime, and the economy. Züri Can seeks to gather relevant data that could influence future policy decisions regarding cannabis in Switzerland and globally.
For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.
Within the Züri Can project, participants have the opportunity to legally purchase cannabis at one of 21 designated locations, including pharmacies, the Drug Information Center (Drogeninformationszentrum), and Cannabis Social Clubs. Pharmacies offer professional health advice, the DIC specializes in promoting safe recreational drug use, and social clubs provide a space for social cannabis consumption and experience exchange. This variety of access points aims to study the impact of different distribution environments on consumption and related behaviors.
Examining the demographics of the Züri Can project participants reveals a clear age diversity. The largest group consists of individuals aged 28 to 32, accounting for over 23% of participants. Significant participation also comes from the 23-27 and 33-37 age groups. Interestingly, the project attracts participants from a wide age spectrum, even beyond 50 years, indicating diverse needs and experiences related to cannabis consumption.
As for participant gender, men dominate, comprising about 80% of all registered, while women represent 18%, and non-binary individuals 1.2%. Such demographic distributions align with general trends observed in cannabis user studies but also highlight the need to understand unique consumption patterns and behaviors by gender.
An analysis of consumption frequency showed that the largest group of Züri Can participants, over half, consumed cannabis at least four times a week before starting the experiment. A significant portion of participants used cannabis two to three times a week. These data indicate a high level of engagement and regularity in consumption among participants, providing important information for analyzing potential changes in consumer behaviors within the project.
Cannabis use disorders can manifest in various ways and severity levels. Within the Züri Can project, it was noted that a certain percentage of participants experienced issues related to cannabis use before joining the program. With regulated cannabis availability, participants can purchase products with specified and controlled THC and CBD concentrations, potentially reducing risk and ensuring user safety. Additionally, access to professional advice and support within the project can help individuals with disorders manage their consumption habits and possible treatments.
The Züri Can project offers a diverse range of cannabis products, including dried flower buds and hashish. The assortment features various THC to CBD ratios, allowing users to tailor the product to their preferences. All products must meet strict Swiss quality standards, including cultivation in line with medicinal plant agricultural practices and organic certification. The genotype variety reflects the diversity of effects users may desire, from Sativa-dominant strains to Indica.
So far, all products have been purchased by Züri Can participants, totaling about 16,500 cannabis product units, including approximately 140 kg of cannabis in 5-gram packages (equivalent to 28,000 packages).
Cannavigia, a European cannabis cultivation company, collaborates with the Swiss Federal Office of Public Health in a study aimed at tracking cannabis sales and providing consumption trend data through its Cannabis Distribution System.
According to Tobias Viegener, Cannavigia’s head of marketing, the preliminary Züri Can results already offer significant insights.
“The initial data from the pilot project ZüriCan, published this month, reveal promising insights about the functionality of a regulated cannabis market and its acceptance among participants,” he told Forbes. “This level of engagement indicates a positive reception and an effective distribution system, laying a solid foundation for future marijuana policy and regulation.”
—
(Featured image by Kindel Media via Pexels)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The DEA has postponed a key hearing on the reclassification of cannabis. The hearing was…
A new California Department of Public Health report has come out with recommendations for THC…
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…